Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 22, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

March 30, 2028

Conditions
T-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies
Interventions
DRUG

Autologous CD7 CAR T-cell

Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.

DRUG

Prior-HSCT donor-derived CD7 CAR T-cell

Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.

DRUG

New donor-derived CD7 CAR T-cell

Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.

Trial Locations (4)

102206

RECRUITING

Beijing GoBroad Hospital, Beijing

200435

RECRUITING

Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

201418

RECRUITING

Shanghai Liquan Hospital, Shanghai

610083

NOT_YET_RECRUITING

The General Hospital of Western Theater Command PLA, Chengdu

All Listed Sponsors
collaborator

The General Hospital of Western Theater Command

OTHER

collaborator

Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

OTHER

collaborator

Shanghai Liquan Hospital

OTHER

collaborator

Central People's Hospital of Zhanjiang

OTHER

lead

Beijing GoBroad Hospital

OTHER